Publication | Closed Access

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Parp Inhibitor OlaparibSurgical OncologyBreast OncologyMedicinePharmacologyBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyDrug Discovery